- Home
- SMWB vs TLSI Comparison
SMWB vs TLSI Comparison
Compare SMWB & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMWB | TLSI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | Israel | United States |
| Employees | N/A | 110 |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.7M | 267.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SMWB | TLSI |
|---|---|---|
| Price | $2.65 | $4.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $8.13 | $7.00 |
| AVG Volume (30 Days) | ★ 1.7M | 198.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.11 | $41.93 |
| Revenue Next Year | $11.13 | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $3.42 |
| 52 Week High | $10.75 | $7.95 |
Technical Indicators
Market Signals| Indicator | SMWB | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 28.00 | 35.61 |
| Support Level | $2.46 | $3.61 |
| Resistance Level | $7.83 | $5.51 |
| Average True Range (ATR) | 0.22 | 0.39 |
| MACD | 0.11 | -0.06 |
| Stochastic Oscillator | 36.36 | 7.22 |
Price Performance
Historical ComparisonAbout SMWB Similarweb Ltd.
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.